Cargando...
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
BACKGROUND: Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted an open-label, single institution, phase Ib study to assess the safety and toler...
Gardado en:
| Publicado en: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5170897/ https://ncbi.nlm.nih.gov/pubmed/28031816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0194-1 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|